Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Key takeaways of recent quarter & conference call highlights
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
The company plans to submit the IND application by the end of 2021
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Subscribe To Our Newsletter & Stay Updated
